Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Basit Öğe Kaydı
dc.contributor.authorArtac, Mehmet
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorKocer, Murat
dc.contributor.authorTurhal, Nazim Serdar
dc.contributor.authorEngin, Huseyin
dc.contributor.authorDede, Isa
dc.date.accessioned2024-02-23T14:02:27Z
dc.date.available2024-02-23T14:02:27Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractSurvival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect. Background: We aimed to investigate the outcomes of interferon alfa and sequencing tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma. Patients and Methods: This multicenter study assessing the efficacy of TKIs after interferon alfa therapy in the first-line setting in patients with metastatic renal cell carcinoma. Patients (n = 104) from 8 centers in Turkey, who had been treated with interferon alfa in the first-line setting, were included in the study. Prognostic factors were evaluated for progression-free survival (PFS). Results: The median age of the patients was 57 years. The median PFS of the patients treated with interferon alfa in the first-line was 3.6 months. A total of 61 patients received TKIs (sunitinib, n = 58; sorafenib, n = 3) after progression while on interferon alfa. The median PFS among the TKI-treated patients was 13.2 months. In the univariate analysis for interferon alfa treatment, neutrophil and hemoglobin level, platelet count, and Karnofsky performance status were the significant factors associated with PFS. In the univariate analysis for TKI treatment, neutrophil and hemoglobin levels were the significant factors for PFS. The median total PFS of the patients who had been treated with first-line interferon alfa and second-line TKIs was 24.9 months. Conclusion: This study showed that first-line interferon alfa treatment before TKIs may improve the total PFS in patients with metastatic renal cell carcinoma. (C) 2016 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clgc.2016.04.021
dc.identifier.endpageE353en_US
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue4en_US
dc.identifier.pmid27236771en_US
dc.identifier.scopus2-s2.0-84969704099en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpageE347en_US
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2016.04.021
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11723
dc.identifier.volume14en_US
dc.identifier.wosWOS:000380760500024en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCytokine Therapyen_US
dc.subjectVegf Inhibitorsen_US
dc.subjectProgression Free Survivalen_US
dc.subjectSorafeniben_US
dc.subjectSunitiniben_US
dc.titleUsing Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu